drugset / Trial / NCT01664728
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide access to abiraterone acetate for patients who have completed 12 cycles of abiraterone acetate treatment in Clinical Study COU-AA-001 and continue to receive clinical benefit from this treatment.
Timeline
- Start
- 2007-04
- Primary completion
- 2009-02
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | 0.5 mg | Oral |
| Background | Prednisolone | Other / unclassified | 5 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |